PASG earnings

Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partnership opportunities for clinical-stage pediatric lysosomal storage disease programs including GM1 gangliosidosisManagement to host a webcast presentation to review interim FTD data today at 8:30 a.m. ET

Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β-Gal activity and GM1 gangliosides, similar to healthy controlsDose 2 biomarker responses demonstrated durability up to 12 months after treatmentImagine-1 study participants showed initial evidence of improved survival relative to natural history dataTreated first patient at highest dose level, Dose 3, in July; initial safety and biomarker data from Dose 3 expected by mid-2024Management to host a conference call and webcast today at 8:30 a.m. ET

Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023Planned expansion of Imagine-1 study to treat patients at a higher dose; expect to dose first patient in second half of 2023Plan to report initial safety and biomarker data from Cohort 1 of global upliFT-D trial for frontotemporal dementia in the second half of 2023Ended 2022 with strong cash position; cash runway into the first half of 2025Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, March 06, 2023 (GLOBE NEW

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 6, 2023 to report its fourth quarter and full-year 2022 financial results and discuss recent business highlights. To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call. About Passage BioPassage Bio (NASDAQ:

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna administration of PBGM01 resulted in dose-dependent increases in CSF β-Gal activity and decreases in CSF GM1 gangliosidesPBGM01 administration resulted in a meaningful improvement across developmental areas in a subset of patients, as assessed by investigators and caretakersCompleted dosing of all patients in dose-ascending portion of study; initial safety and biomarker data from Cohort 4 expected by mid-2023Management to host a conference call and webcast today at 8:30 a.m. ET PHILADELPHIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc

Dosed first patient in final cohort, Cohort 4, in dose-ascending phase of Imagine-1 clinical trial for GM1 gangliosidosis; expect to dose the final patient in this phase of the trial by year-endPlan to report initial safety and biomarker data from Cohorts 2 and 3 of Imagine-1 trial in December 2022Dosed first patient in Cohort 1 of upliFT-D clinical trial for frontotemporal dementiaCompany to streamline operations and refocus strategy, advancing Imagine-1 clinical trial for GM1 gangliosidosis,upliFT-D clinical trial for frontotemporal dementia and preclinical pipeline in adult CNS indicationsCash runway extended into 1H 2025 Management to host conference call today at 8:30 a.m. ET PHILADELP

PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 10, 2022, to report its third quarter 2022 financial results and discuss recent business updates. To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call. About Passage BioPassage Bio (NASDAQ:PASG) is a

Advanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase of study following recommendation by Independent Data Monitoring Committee Presented encouraging longer-term clinical and biomarker data from Cohort 1 in Imagine-1 study at ASGCT; interim safety and biomarker data for Cohorts 2 and 3 expected in 2H22Received IND clearance for Phase 1 clinical program of PBML04 for metachromatic leukodystrophyEnded 2Q22 with strong cash position; cash on hand to fund operations into 2Q24Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinica

PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results and discuss recent business highlights. To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call. About Passage Bio Passage Bio (NASDAQ:PASG) is

Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22Dosed first patient in Cohort 1 in GALax-C clinical trial in infantile Krabbe disease; interim safety and biomarker data expected by year-end 2022Submitted IND for Phase 1/2 clinical program of PBML04 for metachromatic leukodystrophy Completed strategic prioritization to extend cash runway into 2Q24Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformat

PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 16, 2022, to report its first quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 6960234. A live audio webcast of the event will be available on the Investors & News section of Passage Bio's website at investors.passagebio.com. The

Presented positive interim biomarker, safety and efficacy data, including gains in developmental milestones, for Cohort 1 patients in Imagine-1 clinical trial for GM1 gangliosidosisDosed first patients in Cohorts 2 (late infantile, high dose) and 3 (early infantile, low dose) in Imagine-1 trial; interim data for both cohorts expected in second half of 2022Continue to advance and expand robust and differentiated CNS pipeline in partnership with the University of Pennsylvania's Gene Therapy Program Ended 2021 with strong cash position; cash on hand to fund operations to year-end 2023Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) -- Pas

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 4137048. A live audio webcast of the event will be available on the Investors & News section of Passage Bio's website at investors.passageb

Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregiversInterim safety data at three and nine months in Imagine-1 showed low dose PBGM01 well tolerated with no serious adverse events reported and no evidence of dorsal root ganglion toxicityFirst patients dosed in Cohort 2 (late infantile with high dose PBGM01) and Cohort 3 (early infantile with low dose PBGM01); anticipate reporting initial biomarker and safety data in 2H2022Management to host conference call and webcast on Friday, February 11 at 1 p.m. ET PHILADELPHIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio

Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11Podium presentations on clinical trial designs for Imagine-1 and GALax-C, the clinical trial for Krabbe disease, Wednesday, February 9Global Genes poster presentation on Passage Bio-supported patient identification and engagement initiative for rare central nervous system disorders, Tuesday, February 8Management to host conference call and webcast following late-breaker GM1 gangliosidosis presentation on Friday, February 11 at 1 p.m. ET PHILADELPHIA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medici

– Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel – Positive safety profile, including no serious adverse events, no complications related to intra-cisterna magna injection and no evidence of dorsal root ganglion toxicity – Intra-cisterna magna delivery resulted in substantial increases in beta-galactosidase enzyme activity observed in both cerebrospinal fluid and serum – Additional data to be shared in late-breaker presentation at the 18th Annual WORLDSymposium, February 11, 2022 – Management to host a conference call and webcast today at 8 a.m. ET PHILADELPHIA, Dec. 17, 2021 (GLOBE NEW

On track to report initial safety and 30-day biomarker data for cohort 1 from Imagine-1 global Phase 1/2 trial for PBGM01 for the treatment of infantile GM1 in 4Q21Activated multiple clinical sites across three global clinical programs, despite Covid-19 headwinds Expect to dose first participants in global Phase 1/2 trials for PBFT02 and PBKR03 in 4Q21Appointed Maxine Gowen, Ph.D., as chairwoman of the board of directorsManagement to host conference call today at 8:30 a.m. ET PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today

PHILADELPHIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 4, 2021 to report its third quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 2985094. A live audio webcast of the event will be available on the Investors & News section of Passage Bio's website at investors.passagebio.com. The

Expanded strategic collaboration with University of Pennsylvania's Gene Therapy Program to advance genetic medicines for large CNS diseases, initially focused on Alzheimer's Disease and Temporal Lobe EpilepsyExpect to deliver three key clinical milestones in second half of 2021: Dose first patients in global Phase 1/2 trials for PBFT02 and PBKR03 in 3Q21 Report initial safety and 30-day biomarker data from Imagine-1 global Phase 1/2 trial of PBGM01 for the treatment of infantile GM1 in 4Q21 Opened new CMC research and development site in Hopewell, N.J.Appointed three new executives – chief commercial officer, chief financial officer and chief medical officerManagement to host conference call